{"id":5364,"date":"2011-07-28T14:17:00","date_gmt":"2011-07-28T18:17:00","guid":{"rendered":"http:\/\/sciencebusiness.technewslit.com\/?p=5364"},"modified":"2011-07-28T14:17:00","modified_gmt":"2011-07-28T18:17:00","slug":"baxter-sets-up-venture-fund-for-new-therapies","status":"publish","type":"post","link":"https:\/\/technewslit.com\/sciencebusiness\/?p=5364","title":{"rendered":"Baxter Sets Up Venture Fund for New Therapies"},"content":{"rendered":"

\"Money<\/a>Baxter International in Deerfield, Illinois has established Baxter Ventures<\/a> to invest in promising early-stage companies developing therapies that complement Baxter’s product lines. Baxter Ventures will make up to $200 million in equity investments and report to Norbert Riedel, the company’s chief scientific officer.<\/p>\n

Baxter is a developer of medical devices, pharmaceuticals, and biotechnology solutions. The company has focused its R&D in recent years on medical plastics, biologics (e.g., for treatment of hemophilia), and drug delivery solutions. Baxter says it invested $917 million for R&D<\/a> in 2009.<\/p>\n

Baxter Ventures intends to invest globally and focus on technologies with sustainable long-term growth.\u00a0 The company says it will continue its internal investments in R&D and to pursue business development initiatives, collaborations, and alliances.<\/p>\n

Venture capital for the life sciences appears to be on the upswing in the U.S. Biotech and medical device companies were among the companies most favored<\/a> by venture investors in the second quarter of 2011, according to the latest MoneyTree report. Last week, True North Partners announced a $300 million fund<\/a> for early stage enterprises, including those developing innovative solutions in agriculture.<\/p>\n

Read more:<\/p>\n